Novozymes A/S (OTCMKTS:NVZMY) Share Price Crosses Above 50 Day Moving Average – What’s Next?

Novozymes A/S (OTCMKTS:NVZMYGet Free Report)’s share price crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $62.76 and traded as high as $64.55. Novozymes A/S shares last traded at $63.00, with a volume of 16,296 shares.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded shares of Novozymes A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, August 25th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy”.

Check Out Our Latest Report on NVZMY

Novozymes A/S Stock Down 1.8%

The company has a quick ratio of 1.07, a current ratio of 1.75 and a debt-to-equity ratio of 0.28. The firm has a market cap of $29.50 billion, a PE ratio of 39.87, a P/E/G ratio of 1.24 and a beta of 0.97. The firm’s 50 day moving average is $62.76 and its 200-day moving average is $66.14.

Novozymes A/S Cuts Dividend

The business also recently declared a dividend, which was paid on Thursday, September 11th. Investors of record on Wednesday, September 3rd were given a dividend of $0.1856 per share. The ex-dividend date of this dividend was Tuesday, September 2nd. This represents a yield of 88.0%. Novozymes A/S’s dividend payout ratio is 23.42%.

Novozymes A/S Company Profile

(Get Free Report)

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Read More

Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.